These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The ClosER study: results from a three-year pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes, 2011-2014. Freeman J; Vernon J; Pilling S; Morris K; Nicholson S; Shearman S; Longshaw C; Wilcox MH; Clin Microbiol Infect; 2018 Jul; 24(7):724-731. PubMed ID: 29066403 [TBL] [Abstract][Full Text] [Related]
6. High in vitro activity of fidaxomicin against Clostridium difficile isolates from a university teaching hospital in China. Cheng JW; Yang QW; Xiao M; Yu SY; Zhou ML; Kudinha T; Kong F; Liao JW; Xu YC J Microbiol Immunol Infect; 2018 Jun; 51(3):411-416. PubMed ID: 28693926 [TBL] [Abstract][Full Text] [Related]
7. Geographical clustering of cases of infection with moxifloxacin-resistant Clostridium difficile PCR-ribotypes 012, 017 and 046 in Sweden, 2008 and 2009. Akerlund T; Alefjord I; Dohnhammar U; Struwe J; Noren T; Tegmark-Wisell K; Euro Surveill; 2011 Mar; 16(10):. PubMed ID: 21435322 [TBL] [Abstract][Full Text] [Related]
8. The epidemiology of Clostridium difficile in Scotland. Wiuff C; Brown DJ; Mather H; Banks AL; Eastaway A; Coia JE J Infect; 2011 Apr; 62(4):271-9. PubMed ID: 21300104 [TBL] [Abstract][Full Text] [Related]
9. [Epidemiological study of Clostridium difficile strains isolated in Jean-Verdier-René-Muret hospitals from 2001 to 2007]. Poilane I; Fantinato C; Cruaud P; Collignon A Pathol Biol (Paris); 2008; 56(7-8):412-6. PubMed ID: 18842360 [TBL] [Abstract][Full Text] [Related]
10. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications. Debast SB; Bauer MP; Sanders IM; Wilcox MH; Kuijper EJ; J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839 [TBL] [Abstract][Full Text] [Related]
11. Surveillance for antimicrobial resistance in Australian isolates of Clostridium difficile, 2013-14. Knight DR; Giglio S; Huntington PG; Korman TM; Kotsanas D; Moore CV; Paterson DL; Prendergast L; Huber CA; Robson J; Waring L; Wehrhahn MC; Weldhagen GF; Wilson RM; Riley TV J Antimicrob Chemother; 2015 Nov; 70(11):2992-9. PubMed ID: 26221017 [TBL] [Abstract][Full Text] [Related]
12. Two Clusters of Fluoroquinolone and Clindamycin-Resistant Clostridium difficile PCR Ribotype 001 Strain Recognized by Capillary Electrophoresis Ribotyping and Multilocus Variable Tandem Repeat Analysis. Nyc O; Tejkalova R; Kriz Z; Ruzicka F; Kubicek L; Matejkova J; Kuijper E; Krutova M Microb Drug Resist; 2017 Jul; 23(5):609-615. PubMed ID: 27860531 [TBL] [Abstract][Full Text] [Related]
13. Antimicrobial susceptibility patterns of Clostridium difficile strains belonging to different polymerase chain reaction ribotypes isolated in Poland in 2012. Lachowicz D; Pituch H; Obuch-Woszczatyński P Anaerobe; 2015 Feb; 31():37-41. PubMed ID: 25242196 [TBL] [Abstract][Full Text] [Related]
14. U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin. Snydman DR; McDermott LA; Jacobus NV; Thorpe C; Stone S; Jenkins SG; Goldstein EJ; Patel R; Forbes BA; Mirrett S; Johnson S; Gerding DN Antimicrob Agents Chemother; 2015 Oct; 59(10):6437-43. PubMed ID: 26239985 [TBL] [Abstract][Full Text] [Related]
15. Distinct ribotypes and rates of antimicrobial drug resistance in Clostridium difficile from Shanghai and Stockholm. Huang H; Fang H; Weintraub A; Nord CE Clin Microbiol Infect; 2009 Dec; 15(12):1170-3. PubMed ID: 19624517 [TBL] [Abstract][Full Text] [Related]
16. Antimicrobial susceptibility of polymerase chain reaction ribotypes of Clostridium difficile commonly isolated from symptomatic hospital patients in the UK. John R; Brazier JS J Hosp Infect; 2005 Sep; 61(1):11-4. PubMed ID: 16002183 [TBL] [Abstract][Full Text] [Related]
17. Surveillance of antibiotic resistance among common Clostridium difficile ribotypes in Hong Kong. Chow VCY; Kwong TNY; So EWM; Ho YII; Wong SH; Lai RWM; Chan RCY Sci Rep; 2017 Dec; 7(1):17218. PubMed ID: 29222426 [TBL] [Abstract][Full Text] [Related]
18. Association between PCR ribotypes and antimicrobial susceptibility among Clostridium difficile isolates from healthcare-associated infections in South Korea. Kim J; Kang JO; Pai H; Choi TY Int J Antimicrob Agents; 2012 Jul; 40(1):24-9. PubMed ID: 22578765 [TBL] [Abstract][Full Text] [Related]
19. Changes in antibiotic susceptibility and ribotypes in Clostridium difficile isolates from southern Scotland, 1979-2004. Taori SK; Hall V; Poxton IR J Med Microbiol; 2010 Mar; 59(Pt 3):338-344. PubMed ID: 19942691 [TBL] [Abstract][Full Text] [Related]
20. Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection. Gerding DN; Hecht DW; Louie T; Nord CE; Talbot GH; Cornely OA; Buitrago M; Best E; Sambol S; Osmolski JR; Kracker H; Locher HH; Charef P; Wilcox M J Antimicrob Chemother; 2016 Jan; 71(1):213-9. PubMed ID: 26433782 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]